Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PETITE-3TC lamivudine dosing study in preterm infants
PACTR202605762717777Phase 1Not yet recruiting
- Sponsor
- Stellenbosch University
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lamivudine in human immunodeficiency virus infection (HIV), sponsored by Stellenbosch University. Primary endpoint: Lamivudine plasma pharmacokinetics. Planned start May 2026; status: not yet recruiting.
02
Drugs
lamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202605762717777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202605762717777.